Dr. Liu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1111 Highland Ave
WIMR1 Rm 4033
Madison, WI 53705Phone+1 608-265-0106Fax+1 608-234-4383
Summary
- Dr. Hongtao Liu is an oncologist in Madison, WI and is affiliated with University of Wisconsin-Madison. He received his medical degree from Beijing Medical University and has been in practice 24 years. He specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and hematopoietic stem cell transplantation.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2008 - 2011
Texas Tech University (Amarillo)Residency, Internal Medicine, 2005 - 2008
Beijing Medical UniversityClass of 1993
Certifications & Licensure
IL State Medical License 2007 - 2026
WI State Medical License 2023 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Start of enrollment: 2013 Apr 04
- Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission Start of enrollment: 2011 Dec 05
- Selinexor (KPT-330) in Older Patients With Relapsed AML Start of enrollment: 2014 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 142 citationsNext-generation immuno-oncology agents: current momentum shifts in cancer immunotherapyChong-Xian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu
Journal of Hematology & Oncology. 2020-04-03 - 105 citationsEmerging agents and regimens for AMLHongtao Liu
Journal of Hematology & Oncology. 2021-03-23 - 112 citationsSerine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survivalHongtao Liu, Yingyu Ma, Shawn M. Cole, Christopher Zander, Kun Hung Chen
Blood. 2003-07-01
Abstracts/Posters
- Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDSHongtao Liu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH InhibitorsHongtao Liu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
The Immunotherapy RevolutionMay 3rd, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
